Xbiotech Stock Today
| XBIT Stock | USD 2.46 0.05 2.07% |
PerformanceWeakest
| Odds Of DistressLow
|
XBiotech is selling for under 2.46 as of the 23rd of December 2025; that is 2.07 percent increase since the beginning of the trading day. The stock's last reported lowest price was 2.4. XBiotech has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of November 2025 and ending today, the 23rd of December 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of April 2015 | Category Healthcare | Classification Health Care |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company was incorporated in 2005 and is headquartered in Austin, Texas. Xbiotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 30.49 M outstanding shares of which 116.27 K shares are at this time shorted by private and institutional investors with about 0.66 trading days to cover. More on XBiotech
Moving against XBiotech Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
XBiotech Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | John Simard | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsXBiotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand XBiotech's financial leverage. It provides some insight into what part of XBiotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XBiotech (XBIT) is traded on NASDAQ Exchange in USA and employs 88 people. XBiotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 73.48 M. XBiotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 30.49 M outstanding shares of which 116.27 K shares are at this time shorted by private and institutional investors with about 0.66 trading days to cover.
XBiotech currently holds about 225.79 M in cash with (30.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.42, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check XBiotech Probability Of Bankruptcy
Ownership AllocationXBiotech retains a total of 30.49 Million outstanding shares. XBiotech owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company shows, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check XBiotech Ownership Details
XBiotech Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Empowered Funds, Llc | 2025-06-30 | 59.3 K | |
| Bank Of New York Mellon Corp | 2025-06-30 | 48.5 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 48.3 K | |
| Y-intercept (hong Kong) Ltd | 2025-06-30 | 47.9 K | |
| Squarepoint Ops Llc | 2025-06-30 | 39.8 K | |
| Susquehanna International Group, Llp | 2025-06-30 | 39.4 K | |
| Citadel Advisors Llc | 2025-06-30 | 32.5 K | |
| Qube Research & Technologies | 2025-06-30 | 32.2 K | |
| Cubist Systematic Strategies, Llc | 2025-06-30 | 25.9 K | |
| Vanguard Group Inc | 2025-06-30 | 945.4 K | |
| Millennium Management Llc | 2025-06-30 | 551.3 K |
XBiotech Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. XBiotech market risk premium is the additional return an investor will receive from holding XBiotech long position in a well-diversified portfolio.
XBiotech Stock Against Markets
XBiotech Corporate Management
| Benjamn Guzmn | Sr Fin | Profile | |
| Angela Hu | Principal Finance | Profile | |
| Lisa Simard | Inc USA | Profile | |
| Sushma Shivaswamy | Interim Officer | Profile | |
| BA CGA | VP Sec | Profile |
Already Invested in XBiotech?
The danger of trading XBiotech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XBiotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XBiotech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XBiotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.